Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Cathinone or Neuroleptic or None

Use the filters below to narrow your results.

classes: (Click arrow to add another value)
mechanism:
None (1) · 5HT1a (1) · Butyrophenone D2 antagonist (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · NMDA-receptor antagonism (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Phenothiazine D2 antagonist (4) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Source of DMT-class tryptamines (1) · Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) · Source of [[DMT|N,N-dimethyltryptamine]] (1) · TBD (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) · µ-opioid agonism (1)
routes:

Showing below up to 39 results in range #1 to #39.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)